Puma Biotechnology Free Cash Flow (FCF) History (PBYI)
Puma Biotechnology reported $41.7M in free cash flow for fiscal 2025, an increase of 7.38% from the previous fiscal year, with a free cash flow margin of 18.27%.
View full Puma Biotechnology company overviewPuma Biotechnology free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | $41.7M | $2.9M | +7.38% | +18.27% |
| 2024 | 2024-12-31 | $38.9M | $12.0M | +44.64% | +16.86% |
| 2023 | 2023-12-31 | $26.9M | $42.7M | — | +11.40% |
| 2022 | 2022-12-31 | −$15.8M | −$36.5M | — | −6.94% |
| 2021 | 2021-12-31 | $20.6M | $19.9M | +2740.44% | +8.16% |
| 2020 | 2020-12-31 | $727,000 | −$21.3M | −96.71% | +0.32% |
| 2019 | 2019-12-31 | $22.1M | $46.6M | — | +8.11% |
| 2018 | 2018-12-31 | −$24.5M | $148.4M | — | −9.78% |
| 2017 | 2017-12-31 | −$172.9M | −$26.9M | — | −624.53% |
| 2016 | 2016-12-31 | −$146.0M | $9.5M | — | — |
| 2015 | 2015-12-31 | −$155.5M | −$77.2M | — | — |
| 2014 | 2014-12-31 | −$78.3M | −$22.6M | — | — |
| 2013 | 2013-12-31 | −$55.7M | −$53.6M | — | — |
| 2011 | 2011-12-31 | −$2.1M | — | — | — |
Puma Biotechnology quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.6M | −$12.4M | −88.45% | +2.87% |
| Q1 2026 | 2026-03-31 | $15.4M | $11.9M | +334.13% | +34.40% |
| Q4 2025 | 2025-12-31 | $14.4M | −$1.2M | −7.75% | +19.06% |
| Q3 2025 | 2025-09-30 | $9.7M | −$1.4M | −12.30% | +17.74% |
| Q2 2025 | 2025-06-30 | $14.1M | $13.1M | +1296.43% | +26.82% |
| Q1 2025 | 2025-03-31 | $3.6M | −$7.7M | −68.42% | +7.72% |
| Q4 2024 | 2024-12-31 | $15.6M | $5.0M | +47.25% | +26.39% |
| Q3 2024 | 2024-09-30 | $11.0M | −$6.2M | −36.16% | +13.68% |
| Q2 2024 | 2024-06-30 | $1.0M | −$702,000 | −41.08% | +2.14% |
| Q1 2024 | 2024-03-31 | $11.2M | $4.3M | +62.14% | +25.70% |
| Q3 2023 | 2023-09-30 | $10.6M | $18.2M | — | +18.87% |
| Q3 2022 | 2022-09-30 | $17.3M | $35.1M | — | +30.22% |
| Q3 2020 | 2020-09-30 | $1.7M | $8.0M | — | +3.37% |
| Q4 2018 | 2018-12-31 | $6.9M | $42.7M | — | +9.76% |
| Q3 2018 | 2018-09-30 | −$7.6M | $47.5M | — | −12.08% |
| Q2 2018 | 2018-06-30 | −$17.8M | $28.1M | — | −35.14% |
| Q1 2018 | 2018-03-31 | −$6.3M | $29.9M | — | −9.46% |
| Q4 2017 | 2017-12-31 | −$35.8M | $5.8M | — | — |
| Q3 2017 | 2017-09-30 | −$55.1M | −$20.1M | — | −906.06% |
| Q2 2017 | 2017-06-30 | −$45.9M | −$11.5M | — | — |
| Q1 2017 | 2017-03-31 | −$36.2M | −$1.1M | — | — |
| Q4 2016 | 2016-12-31 | −$41.5M | −$8.2M | — | — |
| Q3 2016 | 2016-09-30 | −$35.0M | $2.0M | — | — |
| Q2 2016 | 2016-06-30 | −$34.4M | $325,000 | — | — |
| Q1 2016 | 2016-03-31 | −$35.1M | $15.4M | — | — |
| Q4 2015 | 2015-12-31 | −$33.3M | −$8.9M | — | — |
| Q3 2015 | 2015-09-30 | −$37.0M | −$27.9M | — | — |
| Q2 2015 | 2015-06-30 | −$34.8M | −$31.8M | — | — |
| Q1 2015 | 2015-03-31 | −$50.5M | −$50.3M | — | — |
| Q3 2014 | 2014-09-30 | −$24.4M | — | — | — |
| Q2 2012 | 2012-06-30 | −$9.0M | — | — | — |
| Q1 2012 | 2012-03-31 | −$3.0M | — | — | — |
| Q3 2011 | 2011-09-30 | −$143,218 | — | — | — |
Puma Biotechnology free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from $727,000 to $41.7M, a compound annual growth rate of 124.79%. Puma Biotechnology's latest reported quarter, Q2 2026, generated $1.6M in free cash flow, a decrease of 88.45% year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Puma Biotechnology filings at SEC.gov ↗